(93 days)
The ThyroChek whole blood, rapid TSH assay is a visual, non-instrument, qualitative, solid-phase, lateral now, immunochromatographic assay for identifiying capillary or venous blood sample contains TSH in a concentration ≥ 5 micro IU/ml. The test is intended for use as an in-vitro diagnostic device by medical professionals to screen for primary hypothryoidism. It is not indicated for use as a screening method for neonatal hypothyroidism.
This new immunometric assay device is a single-use Class II medical device for professional use that is designed to indicate whether a capillary or venous blood sample contains TSH in a concentration ≥ 5 micro IU/ml. The ThyroChek whole blood, rapid TSH assay is a visual, non-instrument, qualitative, solid-phase, lateral now, immunochromatographic assay.
{
"1. A table of acceptance criteria and the reported device performance": {
"Acceptance Criteria": [
"Analytic sensitivity between 4.06-5.62 micro IU/ml (quantitative recovery data)",
"Analytic sensitivity between 4.57-5.87 micro IU/ml (serial dilution data)",
"Functional sensitivity of 5.0 micro IU/ml",
"% agreement in identifying specimens with TSH>5 micro IU/ml compared to predicate second / third generation TSH assays = 99%",
"% agreement in identifying specimens with TSH>5 micro IU/ml compared to predicate serum-based one-step rapid TSH assay = 99%",
"No intraassay variation with 10 aliquots at 5 TSH concentrations (coefficient of variation = 0)",
"Assay performance not affected by hCG up to 82,500 mIU/ml",
"Assay performance not affected by LH / FSH > 25 mIU/ml",
"Assay performance not affected by hematocrit between 14-65%",
"Assay performance not affected by azotemia with BUN up to 70 mg% and creatinine up to 8.6 mg%",
"Assay performance not affected by hyperglycemia with blood sugars up to 707 mg%",
"Assay performance not affected by hyperlipidemia with serum triglycerides up to 844 mg%"
],
"Reported Device Performance": [
"Quantitative recovery data demonstrates analytic sensitivity between 4.06-5.62 micro IU/ml.",
"Serial dilution data demonstrates analytic sensitivity between 4.57-5.87 micro IU/ml.",
"Parallelism demonstrates functional sensitivity of 5.0 micro IU/ml.",
"Parallelism demonstrates % agreement in identifying specimens with TSH>5 micro IU/ml compared to predicate second / third generation TSH assays = 99%.",
"Parallelism demonstrates % agreement in identifying specimens with TSH>5 micro IU/ml compared to predicate serum-based one-step rapid TSH assay = 99%.",
"Replicated testing with 10 aliquots at 5 TSH concentrations showed no intraassay variation (coefficient of variation = 0).",
"Assay performance is not affected by hCG in concentrations up to 82,500 mIU/ml.",
"Assay performance is not affected by LH / FSH in concentrations > 25 mIU/ml.",
"Assay performance is not affected by hematocrit between 14-65%.",
"Assay performance is not affected by azotemia with BUN up to 70 mg% and creatinine up to 8.6 mg%.",
"Assay performance is not affected by hyperglycemia with blood sugars up to 707 mg%.",
"Assay performance is not affected by hyperlipidemia with serum triglycerides up to 844 mg%."
]
},
"2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)": "The sample size and data provenance (country of origin, retrospective/prospective) for the test set are not specified in the provided text.",
"3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)": "The number and qualifications of experts for establishing ground truth are not specified in the provided text.",
"4. Adjudication method (e.g. 2+1, 3+1, none) for the test set": "The adjudication method for the test set is not specified in the provided text.",
"5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance": "A multi-reader multi-case (MRMC) comparative effectiveness study was not conducted as this device is a standalone in-vitro diagnostic assay, not an AI-assisted reading tool for human readers.",
"6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done": "Yes, a standalone performance study was done for the 'ThyroChek One-Step Whole Blood Rapid TSH Assay,' as it is a qualitative, solid-phase, lateral-flow immunochromatographic assay designed to be read visually by medical professionals. The reported values directly reflect the device's performance.",
"7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)": "The ground truth appears to be based on comparisons to legally marketed predicate devices, including second and third-generation TSH immunoassays, and a serum-based lateral flow immunochromatographic assay. This indicates that the ground truth is established by reference to established laboratory methods for TSH measurement.",
"8. The sample size for the training set": "The sample size for the training set is not specified in the provided text, as this is a traditional immunoassay and not an AI/machine learning model that typically undergoes a 'training' phase.",
"9. How the ground truth for the training set was established": "Not applicable, as this is a traditional immunoassay, not an AI/machine learning model with a distinct training set and ground truth establishment methodology in the AI context."
}
{0}------------------------------------------------
2 1935 JUN
15. SMDA Summary
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. This new immunometric assay device is a single-use Class II medical device for professional use that is designed to indicate whether a capillary or venous blood sample contains TSH in a concentration ≥ 5 micro IU/ml. The intended use, technical characteristics, efficacy, and safety of this new device are substantially equivalent at detecting TSH > 5 micro IU/ml to a number of other TSH immunoassays that have been commercially available both before and after 1978, and Little Nell Labs believes that demonstration of substantial equivalence to a legally marketed predicate device in accordance with section 510(k) has been demonstrated.
This document contains the results of a number of validation studies which compare the performance of the whole blood rapid TSH assay at detecting TSH > 5 micro IU/ml to that of predicate medical devices, including second (K853717) and third (K930007) generation TSH immunoassays, and to a serum-based lateral flow immunochromatographic assay (K960195). The results obtained are as follows:
-
Quantitative recovery data demonstrates analytic sensitivity between 4.06-5.62 micro IU/ml.
-
Serial dilution data demonstrates analytic sensitivity between 4.57-5.87 micro IU/ml.
-
Parallelism demonstrates:
- a. functional sensitivity of 5.0 micro IU/ml.
- b. % agreement in identifying specimens with TSH>5 microlU/ml
- compared to predicate second / third generation TSH assays = 99%
- c. % agreement in identifying specimens with TSH>5 microlU/ml compared to predicate serum-based one-step rapid TSH assay = 99%.
- Replicated testing with 10 aliquots at 5 TSH concentrations showed no intraassay variation (coefficient of variation = 0).
5. Specificity and Interference. Assay performance is not affected by:
- a. hCG in concentrations up to 82,500 mIU/ml
- b. LH / FSH in concentrations > 25 mIU/ml
- c. hematocrit between 14-65%
- d. azotemia with BUN up to 70 mg% and creatinine up to 8.6 mg%
- e. hyperglycemia with blood sugars up to 707 mg%
- f. hyperlipidemia with serum triglycerides up to 844 mg%.
This 510(k) Summary Statement was prepared by J. Ehrenkranz, M.D., Little Nell Labs, Inc. 1676 E. Sopris Creek Road, Basalt, Co. 81621, 970-927-5253, on 21 May 1999.
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling a stylized caduceus or a representation of the human form, composed of three curved lines and two wavy lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
2 1999 JUN
Joel R.L. Ehrenkranz, M.D. Little Nell Labs Inc./Third World Diagnostics, Inc. 1676 East Sopris Creek Road Basalt, CO 81621
Re: K990658
Trade Name: ThyroChek One-Step Whole Blood Rapid TSH Assay Regulatory Class: II Product Code: JLW Dated: May 07, 1999 Received: May 13, 1999
Dear Dr. Ehrenkranz:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{2}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely vours,
Steven Putman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
| Labels | Values |
|---|---|
| 510(k) Number (if known): | K990658 |
| Device Name: | Thyro Chele one-step whole bland |
| raped TSH assay |
Indications For Use
Jian Cooper
(Division Sign-Off) Division of Clinical Laboratory Devices K990658 510(k) Number _
The ThyroChek whole blood, rapid TSH assay is a visual, non-instrument, qualitative, solid-The THYFOOTOK WHOlO Lister repunochromatographic assay for identifiying capillary or phase, lateral now, ewatern TSH>5 microlU/ml. The test is intended for use as an in-vitro diagnostic device by medical professionals to screen for primary hypothryoidism. It is not indicated for use as a screening method for neonatal hypothyroidism.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
§ 862.1690 Thyroid stimulating hormone test system.
(a)
Identification. A thyroid stimulating hormone test system is a device intended to measure thyroid stimulating hormone, also known as thyrotrophin and thyrotrophic hormone, in serum and plasma. Measurements of thyroid stimulating hormone produced by the anterior pituitary are used in the diagnosis of thyroid or pituitary disorders.(b)
Classification. Class II.